GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Gross Profit

Lyka Labs (BOM:500259) Gross Profit : ₹663 Mil (TTM As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Gross Profit?

Lyka Labs's gross profit for the three months ended in Mar. 2024 was ₹158 Mil. Lyka Labs's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ₹663 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Lyka Labs's gross profit for the three months ended in Mar. 2024 was ₹158 Mil. Lyka Labs's Revenue for the three months ended in Mar. 2024 was ₹278 Mil. Therefore, Lyka Labs's Gross Margin % for the quarter that ended in Mar. 2024 was 56.88%.

Lyka Labs had a gross margin of 56.88% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Lyka Labs was 70.97%. The lowest was 35.35%. And the median was 47.07%.


Lyka Labs Gross Profit Historical Data

The historical data trend for Lyka Labs's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Gross Profit Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.14 289.23 1,302.84 555.18 663.43

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.99 133.67 162.96 208.84 157.95

Competitive Comparison of Lyka Labs's Gross Profit

For the Biotechnology subindustry, Lyka Labs's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Gross Profit distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Gross Profit falls into.



Lyka Labs Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Lyka Labs's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=1111.946 - 448.517
=663

Lyka Labs's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=277.673 - 119.724
=158

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹663 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Lyka Labs's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=158 / 277.673
=56.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Lyka Labs  (BOM:500259) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Lyka Labs had a gross margin of 56.88% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Lyka Labs Gross Profit Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines